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Two major intracellular receptors for cGMP in smooth
muscle are cGMP-dependent protein kinase (PKG) and
phosphodiesterase-5 (PDE5), the latter of which contains
both hydrolytic and allosteric sites for cGMP. We have
shown that either one or both of these enzymes are
involved in at least eight events leading to negative feed-
back control after nitric oxide-induced cGMP elevation: 1)
increased hydrolysis of cGMP due to substrate elevation;
2) activation of PKG, which phosphorylates and activates
PDE5; 3) enhanced phosphorylation of PDE5 by PKG due
to exposure of the PDE5 phosphorylation site by elevated
PDE5 hydrolytic site occupancy; 4) enhanced phosphor-
ylation of PDE5 by PKG due to exposure of the PDE5
phosphorylation site by elevated PDE5 allosteric site
occupancy; 5) increased sequestration of cGMP by PDE5
allosteric sites; 6) stimulation of PDE5 allosteric site occu-
pancy by increased hydrolytic site occupancy; 7) stimula-
tion of PDE5 allosteric site occupancy by increased
phosphorylation of PDE5; and 8) conversion of PDE5 to
a more active conformer by increased hydrolytic site occu-
pancy. In concert, these events are predicted to result in
increased cGMP breakdown and sequestration, producing
negative feedback after cGMP elevation. The events could
be explained by the presence of two interconvertible
forms of PDE5: a less active conformer and a more active
conformer that has increased cGMP hydrolytic activity,
cGMP allosteric binding, and phosphorylation. By native
PAGE (no SDS), cGMP or phosphorylation causes a gel
shift consistent with a conformational change, and hydro-
lytic site-specific inhibitors such as sildenafil, vardenafil,
and tadalafil cause a similar shift. Combined studies of x-
ray crystal structures and site-directed mutagenesis iden-
tify three key amino acids (human Tyr-612, Gln-817, and
Phe-820) in the PDE5 catalytic site that contribute impor-
tantly to high affinity of cGMP as well as potency and
selectivity for PDE5 inhibitors. Binding of each of these
ligands can initiate several of the cGMP feedback proc-
esses mediated by PDE5.
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